History

The Story

Onyx is a 20-year-old contract manufacturer that became a public company 18 months ago, in November 2024. Its full disclosure footprint is one annual report, one prospectus, two presentations, and 18 months of price action. The story is short and has already turned: an IPO sold on capacity expansion and margin expansion was followed, two reporting periods later, by margin collapse and a full-year net loss. The promoter team has delivered the mechanical promises (debt repayment, Unit-II ramp) and has been silent on the larger ones (margin trajectory, international expansion, the Large Volume Parenterals brand). Credibility is not broken — no scandals, no auditor flags, no governance accidents — but it is leaking.

1. The Narrative Arc

The current strategic chapter starts in 2023, when Unit-II came online and changed the business from a single-product SWFI supplier into a three-format contract manufacturer (sterile water, dry powder injections, dry syrups). The MD, Sanjay Jain, has run operations since 2008 but was only formally appointed Managing Director on July 23, 2024 — four months before the IPO. So the present management is also the founding management; this is not a turnaround team inheriting someone else's company.

Why this matters

• The IPO valuation rested on a single year of accelerating profitability (FY24 → FY25) on capacity that had just been installed. There is no long-arc track record to fall back on.
• FY2026 — the first full fiscal year as a listed company — was a net loss. That is not the inflection point management's IPO marketing pointed at.

2. What Management Emphasized — and Then Stopped Emphasizing

The IPO prospectus (Nov 2024) and the FY25 Annual Report (May 2025) cover almost the same window but their relative emphasis on key themes shifts meaningfully. The heatmap below codes how much space each theme received (0 = absent, 5 = repeated headline).

Topic emphasis: IPO marketing vs first AR as a listed company.

Three patterns stand out:

• The own-brand LVP line dropped out of the narrative. The IPO earmarked ₹6.07 crore — the single largest non-debt use of proceeds — to upgrade Unit-I to produce Large Volume Parenterals under the Onyx brand. The FY25 AR does not mention LVPs, an LVP launch timeline, or a brand-building plan. The capex object has gone quiet.
• Exports collapsed in the narrative because they had no underlying activity. The RHP repeatedly described "India and overseas" markets. The FY25 AR's Annexure 2 reports Foreign Exchange earnings: NIL and Foreign Exchange outgo: NIL for both FY24 and FY25. The export pillar exists in the prospectus and not in the financials.
• India-macro padding expanded as company-specific content thinned. The FY25 MD&A spends roughly twice as much space on IMF/World Bank GDP commentary, US fiscal policy and India pharma sector statistics as it does on Onyx itself. That is a tell.

3. Risk Evolution

Onyx's NSE SME annual report is not required to carry a SEC-style Risk Factors section. The IPO RHP filed 33 internal risk factors (Nov 2024); the FY25 AR's MD&A "Risks and Concerns" is a one-paragraph cautionary statement. Below: how the substance of those risks has actually played through the first 18 months of public-company life.

Risk evolution — disclosed at IPO vs realized over FY26.

The risks that have actually moved are profitability and working capital, neither of which the prospectus flagged as a top-tier concern.

Debtor days have nearly tripled (47 → 144) in three years; the cash conversion cycle more than tripled. The IPO RHP disclosed the concept of payment-delay risk but the disclosed FY22–H1-FY25 numbers did not look stressed. They look stressed now.

4. How They Handled Bad News

Onyx's first piece of bad news as a listed company arrived in the H1 FY26 disclosure (filed early November 2025). Operating margin had collapsed from 18.94% in H1 FY25 to 2.72% in H1 FY26 — a drop of more than 16 percentage points in a single half. The half closed in a net loss.

Three behaviors deserve attention:

• Silence. NSE SME companies do not host quarterly earnings calls, but they are allowed to. Onyx did not. There is no investor communication explaining the H1 FY26 collapse — no press release, no presentation, no statement on the company site. The only public commentary is third-party (MarketsMojo coverage on Sept 19 and Sept 29, 2025) noting "the lack of available positive or negative factors further complicates the outlook, as there are no specific catalysts mentioned."
• The dividend signal. The FY25 AR justified the dividend skip with: "To strengthen the financial position of the Company and to augment working capital, your directors do not recommend any dividend for the FY 2025." In hindsight that is consistent with a board that already knew working capital was tight — debtor days went from 119 (FY25) to 144 (FY26).
• A 100% rise in managerial remuneration, in the year before the loss. The FY25 AR discloses that managerial remuneration rose 100% during FY25 vs 23% for the median employee. That increase was approved before management had visibility into the FY26 margin collapse — but the optics of a doubled MD payslip immediately before a swing-to-loss year are poor, and management has not addressed them.

5. Guidance Track Record

Onyx has made very few formal guidance statements. The promises that mattered to valuation were embedded in the IPO Objects of the Issue and the strengths section of the RHP. Here is the scorecard for the ones a buyer would have cared about.

Why 4/10. The mechanical, calendar-driven promises (raise the IPO, repay the debt, hold the promoter stake, keep WHO-GMP, stay clean on related parties) have all been delivered. The promises that required operating execution under public-company scrutiny — own-brand LVP launch, export build-out, margin sustainability, profit growth — have either failed (exports, FY26 profit) or gone silent (LVP, cartoning, margin trajectory). The score is not lower because there is no evidence of fraud, no auditor qualification, no regulatory penalty, and no governance accident. The score is not higher because the company has not communicated through the first real test, and because the IPO marketing materially understated working-capital risk that has now crystallized.

6. What the Story Is Now

The current story is much simpler than the IPO pitch, and meaningfully less attractive.

What has been de-risked:

• Capital structure is no longer the binding constraint. Net debt is small (~₹15 cr at FY26-end on equity of ~₹55 cr). The promoter group still owns 65%, with credible alignment.
• The regulatory footprint is clean. WHO-GMP for both units, no auditor qualifications, no SEBI/SEBI-LODR penalties, no IBC proceedings, no material litigation.
• Capacity exists. Unit-II is built. The bottleneck is no longer manufacturing capacity.

What still looks stretched:

• Operating margin. FY26 op margin (4.89%) is the worst of the five reported years. The 16-percentage-point collapse from H1 FY25 to H1 FY26 has not been explained.
• Working capital. Debtor days of 144 and a cash conversion cycle near 120 days for a contract manufacturer with ₹69 cr of revenue is not viable. Either the customer mix is shifting toward weaker payers, or order book quality is dropping. Neither has been disclosed.
• The own-brand LVP line. The single biggest IPO-narrative item beyond debt repayment has gone silent. If it launches, the story is alive; if it never appears, the IPO documentation was aspirational.
• The export pillar. Currently zero. The prospectus treated "overseas" as a forward growth lever; the AR confirms it has produced no foreign exchange.

What the reader should believe versus discount:

• Believe the disclosed financial trajectory through FY26 — the auditors haven't qualified anything and the half-yearly breaks are internally consistent.
• Believe that the promoter family is committed (65% holding, personal guarantees still in place against bank facilities).
• Discount the "international" and "own-brand LVP" portions of the IPO pitch until the company publishes concrete evidence (first export invoice, first LVP order, first commissioning announcement).
• Discount any inference that management will proactively explain operating misses. The H1 FY26 collapse was met with silence; treat that as the base case for future bad news.